Drugs

, Volume 68, Issue 6, pp 725–736

Therapy for Helicobacter pylori Infection Can be Improved

Sequential Therapy and Beyond
Current Opinion

Abstract

As with other bacterial infections, successful treatment of Helicobacter pylori infections depends on the use of antibacterial agents to which the organism is susceptible. In this article, we use the proposed report card grading scheme (i.e. grade A, B, C, D, F) for the outcome of clinical trials, where intention-to-treat cure rates >95% = A, 90–95% = B, 85–89% = C, 81–84% = D and <81% = F. The goal of therapy is to consistently cure >95% of patients (e.g. provide grade A results). Like tuberculosis, H. pylori infections are difficult to cure and successful treatment generally requires the administration of several antibacterial agents simultaneously. Duration of therapy is also important and depends upon whether resistance is present; 14 days is often best. With few exceptions, worldwide increasing macrolide resistance now undermines the effectiveness of the legacy triple therapy (e.g. a proton pump inhibitor [PPI], clarithromycin and amoxicillin) and, in most areas, cure rates have declined to unacceptable levels (e.g. grade F).

The development of sequential therapy was one response to this problem. Sequential therapy has repeatedly been shown in head-to-head studies to be superior to legacy triple therapy. Sequential therapy, as originally described, is the sequential administration of a dual therapy (a PPI plus amoxicillin) followed by a Bazzoli-type triple therapy (a PPI plus clarithromycin and tinidazole) and has been shown to be especially useful where there is clarithromycin resistance. However, the cure rates of the original sequential treatment are grade B and can probably be further improved by changes in dose, duration or administration, such as by continuing the amoxicillin into the triple therapy arm. The sequential approach may also be more complicated than necessary, based on the fact that the same four drugs have also been given concomitantly (at least nine publications with >700 patients) as a quadruple therapy with excellent success.

This article discusses the approach to therapy in the modern era where antimicrobial resistance is an increasing problem and legacy triple therapy is no longer an acceptable initial choice. Methods to achieve acceptable eradication rates (e.g. grade A or B results) are discussed and, specifically, sequential therapy is considered both conceptually and practically. Suggestions are provided regarding how sequential therapy might be improved to become a grade A therapy as well as how to identify situations where it can be expected to yield unacceptable results. New uses for current drugs are discussed and suggestions for subsequent randomized comparisons to overcome phenotypic and genotypic resistance are given. We propose a change in focus from comparative studies (designed to prove that a new therapy is superior to a known inferior therapy) to demanding that efficacious therapies meet or exceed a pre-specified level of success (i.e. grade A or B result). To do so, coupled with less concern about the effect of recommendations on the pharmaceutical industry, should provide clinicians with much higher quality information, and improve the quality of medical care and recommendations regarding treatment. Ultimately, there is little or no justification for comparative testing that includes an arm with known unacceptably low results. H. pylori gastritis is an infectious disease and should be approached and treated as such.

References

  1. 1.
    Cardenas VM, Mulla ZD, Ortiz M, et al. Iron deficiency and Helicobacter pylori infection in the United States. Am J Epidemiol 2006 Jan 15; 163(2): 127–34PubMedCrossRefGoogle Scholar
  2. 2.
    Dholakia KR, Dharmarajan TS, Yadav D, et al. Vitamin B12 deficiency and gastric histopathology in older patients. World J Gastroenterol 2005 Dec 7; 11(45): 7078–83PubMedGoogle Scholar
  3. 3.
    DuBois S, Kearney DJ. Iron-deficiency anemia and Helicobacter pylori infection: a review of the evidence. Am J Gastroenterol 2005 Feb; 100(2): 453–9PubMedCrossRefGoogle Scholar
  4. 4.
    Hershko C, Lahad A, Kereth D. Gastropathic sideropenia. Best Pract Res Clin Haematol 2005 Jun; 18(2): 363–80PubMedCrossRefGoogle Scholar
  5. 5.
    Graham DY. Can therapy ever be denied for Helicobacter pylori infection? [editorial]. Gastroenterology 1997; 113 (6 Suppl.): S113-7Google Scholar
  6. 6.
    Axon A, Forman D. Helicobacter gastroduodenitis: a serious infectious disease. BMJ 1997; 314(7092): 1430–1PubMedCrossRefGoogle Scholar
  7. 7.
    Scott D, Weeks D, Melchers K, et al. The life and death of Helicobacter pylori. Gut 1998; 43 Suppl. 1: S56–60PubMedCrossRefGoogle Scholar
  8. 8.
    Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007 Aug 1; 26(3): 343–57PubMedCrossRefGoogle Scholar
  9. 9.
    Graham DY, Dore MP. Variability in the outcome of treatment of Helicobacter pylori infection: a critical analysis. In: Hunt RH, Tytgat GNJ, editors. Helicobacter pylori basic mechanisms to clinical cure 1998. Dordrecht: Kluwer Academic Publishers, 1998: 426–40Google Scholar
  10. 10.
    Connolly LE, Edelstein PH, Ramakrishnan L. Why is long-term therapy required to cure tuberculosis? PLoS Med 2007 Mar; 4(3): el20CrossRefGoogle Scholar
  11. 11.
    Moayyedi P. Sequential regimens for Helicobacter pylori eradication. Lancet 2007 Sep 22; 370(9592): 1010–2PubMedCrossRefGoogle Scholar
  12. 12.
    Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007 Sep; 133(3): 985–1001PubMedCrossRefGoogle Scholar
  13. 13.
    Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007 Aug; 102(8): 1808–25PubMedCrossRefGoogle Scholar
  14. 14.
    Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007 Jun; 56(8): 772–81PubMedCrossRefGoogle Scholar
  15. 15.
    Storskrubb T, Aro P, Ronkainen J, et al. Antimicrobial susceptibility of Helicobacter pylori strains in a random adult Swedish population. Helicobacter 2006 Aug; 11(4): 224–30PubMedCrossRefGoogle Scholar
  16. 16.
    Zagari RM, Bianchi-Porro G, Fiocca R, et al. Comparison of 1 and 2 weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER Study. Gut 2007 Apr; 56(4): 475–9PubMedCrossRefGoogle Scholar
  17. 17.
    Vakil N, Lanza F, Schwartz H, et al. Seven-day therapy for Helicobacter pylori in the United States. Aliment Pharmacol Ther 2004 Jul 1; 20(1): 99–107PubMedCrossRefGoogle Scholar
  18. 18.
    de Boer WA, van Etten RJ, Lai JY, et al. Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. Helicobacter 1996 Sep; 1(3): 145–50PubMedCrossRefGoogle Scholar
  19. 19.
    de Boer WA, Tytgat GN. How to treat Helicobacter pylori infection: should treatment strategies be based on testing bacterial susceptibility? A personal viewpoint. Eur J Gastroenterol Hepatol 1996; 8(7): 709–16PubMedGoogle Scholar
  20. 20.
    Graham DY. A reliable cure for Helicobacter pylori infection? Gut 1995; 37: 154–6PubMedCrossRefGoogle Scholar
  21. 21.
    Malfertheiner P, Megraud F, O’ Morain C, et al. Current European concepts in the management of Helicobacter pylori infection: the Maastricht Consensus Report. The European Helicobacter pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 1997; 9(1): 1–2PubMedCrossRefGoogle Scholar
  22. 22.
    Bochenek WJ, Peters S, Fraga PD, et al. Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pan-toprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. Helicobacter 2003 Dec; 8(6): 626–42PubMedCrossRefGoogle Scholar
  23. 23.
    Fennerty MB, Kovacs TO, Krause R, et al. A comparison of 10 and 14 days of lansoprazole triple therapy for eradication of Helicobacter pylori. Arch Intern Med 1998 Aug 10; 158(15): 1651–6PubMedCrossRefGoogle Scholar
  24. 24.
    Laine L, Frantz JE, Baker A, et al. A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori. Aliment Pharmacol Ther 1997 Oct; 11(5): 913–7PubMedCrossRefGoogle Scholar
  25. 25.
    Delia MP, Lavagna A, Masoero G, et al. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002 Jul; 16(7): 1269–75CrossRefGoogle Scholar
  26. 26.
    Boixeda D, Martin DA, Bermejo F, et al. Seven-day proton pump inhibitor, amoxicillin and clarithromycin triple therapy. factors that influence Helicobacter pylori eradications success. Rev Esp Enferm Dig 2003 Mar; 95(3): 206–5PubMedGoogle Scholar
  27. 27.
    Calvet X, Ducons J, Bujanda L, et al. Seven versus ten days of rabeprazole triple therapy for Helicobacter pylori eradication: a multicenter randomized trial. Am J Gastroenterol 2005 Aug; 100(8): 1696–701PubMedCrossRefGoogle Scholar
  28. 28.
    De Francesco V, Zullo A, Hassan C, et al. The prolongation of triple therapy for Helicobacter pylori does not allow reaching therapeutic outcome of sequential scheme: a prospective, randomised study. Dig Liver Dis 2004 May; 36(5): 322–6PubMedCrossRefGoogle Scholar
  29. 29.
    De Francesco V, Delia VN, Stoppino V, et al. Effectiveness and pharmaceutical cost of sequential treatment for Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2004 May 1; 19(9): 993–8PubMedCrossRefGoogle Scholar
  30. 30.
    Paoluzi P, Iacopini F, Crispino P, et al. 2-Week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study. Helicobacter 2006 Dec; 11(6): 562–8PubMedCrossRefGoogle Scholar
  31. 31.
    Zagari RM, Bianchi-Porro G, Fiocca R, et al. Comparison of one and two weeks of omeprazole, amoxicillin and clarithromycin treatment for Helicobacter pylori eradication: the HYPER study. Gut 2007 Apr; 56(4): 475–9PubMedCrossRefGoogle Scholar
  32. 32.
    Zullo A, Rinaldi V, Winn S, et al. A new highly effective short-term therapy schedule for Helicobacter pylori eradication. Aliment Pharmacol Ther 2000 Jun; 14(6): 715–8PubMedCrossRefGoogle Scholar
  33. 33.
    Furuta T, Shirai N, Xiao F, et al. Polymorphism of interleukin-1beta affects the eradication rates of Helicobacter pylori by triple therapy. Clin Gastroenterol Hepatol 2004 Jan; 2(1): 22–30PubMedCrossRefGoogle Scholar
  34. 34.
    Furuta T, Sagehashi Y, Shirai N, et al. Influence of CYP2C19 polymorphism and Helicobacter pylori genotype determined from gastric tissue samples on response to triple therapy for H. pylori infection. Clin Gastroenterol Hepatol 2005 Jun; 3(6): 564–73PubMedCrossRefGoogle Scholar
  35. 35.
    Vaira D, Zullo A, Vakil N, et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: arandomized trial. Ann Intern Med 2007 Apr 17; 146(8): 556–63PubMedGoogle Scholar
  36. 36.
    Higuchi K, Maekawa T, Nakagawa K, et al. Efficacy and safety of Helicobacter pylori eradication therapy with omeprazole, amoxicillin and high-and low-dose clarithromycin in Japanese patients: a randomised, double-blind, multicentre study. Clin Drug Investig 2006; 26(7): 403–14PubMedCrossRefGoogle Scholar
  37. 37.
    Murakami K, Sato R, Okimoto T, et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002 Nov; 16(11): 1933–8PubMedCrossRefGoogle Scholar
  38. 38.
    Take S, Mizuno M, Ishiki K, et al. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection. Am J Gastroenterol 2003 Nov; 98(11): 2403–8PubMedGoogle Scholar
  39. 39.
    Kim BG, Lee DH, Ye BD, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007 Feb; 12(1): 31–5PubMedCrossRefGoogle Scholar
  40. 40.
    Zhang L, Shen L, Ma JL, et al. Eradication of H. pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy. World J Gastroenterol 2006 Jun 28; 12(24): 3915–8PubMedGoogle Scholar
  41. 41.
    Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007 Aug; 12(4): 275–8PubMedCrossRefGoogle Scholar
  42. 42.
    Diagnosi e terapia dell’infezione da H. pylori. In: Current concepts in the management of Helicobacter pylori infections: proceedings Atti congressuali. Salerno: Momento Medico, 2005: 81–92Google Scholar
  43. 43.
    Sessione plenaria finale. In: Current concepts in the management of Helicobacter pylori infections: consensus report, comments and current concepts. Salerno: Momento Medico, 2005: 163–5Google Scholar
  44. 44.
    Hopkins RJ. In search of the holy grail of Helicobacter pylori remedies. Helicobacter 2001 Jun; 6(2): 81–3PubMedCrossRefGoogle Scholar
  45. 45.
    Graham DY, Dore MP. The QUADRATE study: a proposal for a change in the reporting of pharmaceutical supported trials [letter]. Gastroenterology 2003 Aug; 125(2): 639PubMedCrossRefGoogle Scholar
  46. 46.
    Graham DY, Yamaoka Y. Ethical considerations of comparing sequential and traditional anti Helicobacter pylori therapy. Ann Intern Med 2007 Sep 18; 147(6): 434–5PubMedGoogle Scholar
  47. 47.
    Graham DY, Yamaoka Y. One-or two-week triple therapy for Helicobacter pylori: questions of efficacy and inclusion of a dual therapy treatment arm. Gut 2007 Jul; 56(7): 1021–3PubMedCrossRefGoogle Scholar
  48. 48.
    de Boer WA, Tytgat GN. The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice? Scand J Gastroenterol 1995; 30: 401–7PubMedCrossRefGoogle Scholar
  49. 49.
    Graham DY, de Boer WA, Tytgat GN. Choosing the best anti-Helicobacter pylori therapy: effect of antimicrobial resistance. Am J Gastroenterol 1996; 91(6): 1072–6PubMedGoogle Scholar
  50. 50.
    Graham DY. Antibiotic resistance in Helicobacter pylori: implications for therapy. Gastroenterology 1998; 115(5): 1272–7PubMedCrossRefGoogle Scholar
  51. 51.
    Zullo A, De FV, et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007 Oct; 56(10): 1353–7PubMedCrossRefGoogle Scholar
  52. 52.
    Fuccio L, Minardi ME, Zagari RM, et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007 Oct 16; 147(8): 553–62PubMedGoogle Scholar
  53. 53.
    Tremaine W. Equipoise, H pylori, and Musketeers choosing an appropriate standard clinical care regimen for randomized trials. Helicobacter. In pressGoogle Scholar
  54. 54.
    Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology 2000; 118 (2 Suppl. 1): S2-8Google Scholar
  55. 55.
    Bazzoli F, Zagari RM, Fossi S, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6: 773–7CrossRefGoogle Scholar
  56. 56.
    de Bortoli N, Leonardi G, Ciancia E, et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol 2007 May; 102(5): 951–6PubMedCrossRefGoogle Scholar
  57. 57.
    Catalano F, Branciforte G, Catanzaro R, et al. Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen. Aliment Pharmacol Ther 2000 Oct; 14(10): 1329–34PubMedCrossRefGoogle Scholar
  58. 58.
    Gisbert JP, Marcos S, Gisbert JL, et al. High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metro-nidazole twice daily for only five days in Helicobacter pylori eradication. Helicobacter 2001 Jun; 6(2): 157–62PubMedCrossRefGoogle Scholar
  59. 59.
    Nagahara A, Miwa H, Ogawa K, et al. Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy. Helicobacter 2000 Jun; 5(2): 88–93PubMedCrossRefGoogle Scholar
  60. 60.
    Nagahara A, Miwa H, Yamada T, et al. Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection. Aliment Pharmacol Ther 2001 Mar; 15(3): 417–21PubMedCrossRefGoogle Scholar
  61. 61.
    Neville PM, Everett S, Langworthy H, et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther 1999; 13(4): 497–501PubMedCrossRefGoogle Scholar
  62. 62.
    Okada M, Oki K, Shirotani T, et al. A new quadruple therapy for the eradication of Helicobacter pylori: effect of pretreatment with omeprazole on the cure rate. J Gastroenterol 1998; 33(5): 640–5PubMedCrossRefGoogle Scholar
  63. 63.
    Okada M, Nishimura H, Kawashima M, et al. A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome. Aliment Pharmacol Ther 1999; 13(6): 769–74PubMedCrossRefGoogle Scholar
  64. 64.
    Treiber G, Ammon S, Schneider E, et al. Amoxicillin/metroni-dazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. Helicobacter 1998; 3(1): 54–8PubMedCrossRefGoogle Scholar
  65. 65.
    Treiber G, Wittig J, Ammon S, et al. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002 Jan 28; 162(2): 153–60PubMedCrossRefGoogle Scholar
  66. 66.
    Wang G, Wilson TJ, Jiang Q, et al. Spontaneous mutations that confer antibiotic resistance in Helicobacter pylori. Antimicrob Agents Chemother 2001 Mar; 45(3): 727–33PubMedCrossRefGoogle Scholar
  67. 67.
    van der Hulst RWM, Keller JJ, Rauws EA, et al. Treatment of Helicobacter pylori infection in humans: a review of the world literature. Helicobacter 1996; 1(1): 6–19PubMedCrossRefGoogle Scholar
  68. 68.
    Bayerdorffer E, Miehlke S, Mannes GA, et al. Double-blind trial of omeprazole and amoxicillin to cure Helicobacter pylori infection in patients with duodenal ulcers. Gastroenterology 1995; 108: 1412–7PubMedCrossRefGoogle Scholar
  69. 69.
    Miehlke S, Mannes GA, Lehn N, et al. An increasing dose of omeprazole combined with amoxycillin cures Helicobacter pylori infection more effectively. Aliment Pharmacol Ther 1997; 11(2): 323–9PubMedCrossRefGoogle Scholar
  70. 70.
    Miehlke S, Kirsch C, Schneider-Brachert W, et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003 Aug; 8(4): 310–9PubMedCrossRefGoogle Scholar
  71. 71.
    Harford W, Lanza F, Arora A, et al. Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. Helicobacter 1996; 1(4): 243–50PubMedCrossRefGoogle Scholar
  72. 72.
    Graham DY, Abudayyeh S, El-Zimaity HM, et al. Sequential therapy using high-dose esomeprazole-amoxicillin followed by gatifloxacin for Helicobacter pylori infection. Aliment Pharmacol Ther 2006 Sep; 24(5): 845–50PubMedCrossRefGoogle Scholar
  73. 73.
    Furuta T, Shirai N, Takashima M, et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin. Pharmacogenetics 2001 Jun; 11(4): 341–8PubMedCrossRefGoogle Scholar
  74. 74.
    Furuta T, Shirai N, Kodaira M, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H pylori. Clin Pharmacol Ther 2007 Apr; 81(4): 521–8PubMedCrossRefGoogle Scholar
  75. 75.
    Shirai N, Sugimoto M, Kodaira C, et al. Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy. Eur J Clin Pharmacol 2007 Aug; 63(8): 743–9PubMedCrossRefGoogle Scholar
  76. 76.
    Bardhan K, Bayerdorffer E, Veldhuyzen van Zanten SJ, et al. The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter 2000 Dec; 5(4): 196–201PubMedCrossRefGoogle Scholar
  77. 77.
    Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116(2): 248–53PubMedCrossRefGoogle Scholar
  78. 78.
    Megraud F, Lehn N, Lind T, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999 Nov; 43(11): 2747–52PubMedGoogle Scholar
  79. 79.
    Lind T, Veldhuyzen van Zanten S, Unge P, et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. Helicobacter 1996; 1(3): 138–44PubMedCrossRefGoogle Scholar
  80. 80.
    Schwartz H, Krause R, Sahba B, et al. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Am J Gastroenterol 1998; 93(4): 584–90PubMedCrossRefGoogle Scholar
  81. 81.
    Schwab M, Schaeffeler E, Klotz U, et al. CYP2C19 polymorphism is a major predictor of treatment failure in white patients by use of lansoprazole-based quadruple therapy for eradication of Helicobacter pylori. Clin Pharmacol Ther 2004 Sep; 76(3): 201–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2008

Authors and Affiliations

  1. 1.Department of MedicineMichael E. DeBakey Veterans Affairs Medical CenterHoustonUSA
  2. 2.Department of MedicineBaylor College of MedicineHoustonUSA
  3. 3.Department of Gastroenterology, Renji HospitalShanghai Jiao Tong University School of Medicine, Shanghai Institute of Digestive DiseaseShanghaiChina

Personalised recommendations